ArticleBMC infectious diseases2025
Analysis of disease burden and trends in non-COVID-19 respiratory infections in China (1990-2021).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Health-Seeking Behaviors After Acute Respiratory Infection Among Urban and Rural Residents and Different Age Groups: Cross-Sectional Questionnaire Study.Journal of medical Internet research · 2026Article
- Evaluating the effectiveness and safety of Xiyanping injection for severe pneumonia: a target trial emulation protocol using real-world data.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFollowing the outbreak of the coronavirus disease (COVID-19) in 2019, there was a lack of systematic data on the disease burden and epidemiological trends of respiratory infections in China.
methodsA systematic analysis of the 2021 Global Burden of Disease Study was conducted to estimate the incidence, mortality, and disability-adjusted life years of upper respiratory infections (URIs) and lower respiratory infections (LRIs) in China. These estimates were stratified according to sex and age. A joinpoint regression model was used to assess the trends in the incidence and mortality of URIs and LRIs in China from 1990 to 2021. The Age-Period-Cohort model was used to calculate the contributions of age, period, and cohort effects to the morbidity and mortality risks of URIs and LRIs in China over the observation period.
resultsIn 2021, the age-standardised incidence rates for URIs and LRIs were 137,469 per 100,000 and 2,853 per 100,000, respectively, representing a decrease of 0.03% and 2.12%, respectively, from 1990. Furthermore, 2,193 deaths from URIs and 206,930 deaths from LRIs were noted in 2021. For URIs, the DALYs decreased from 1,426,557 in 1990 to 649,505 in 2021; for LRIs, they decreased from 32,576,310 in 1990 to 4,106,779 in 2021. The URI and LRI burdens were slightly higher in males compared with females, and they were relatively higher in neonates and the elderly. The incidence and mortality rates of URIs and LRIs were significantly influenced by age, period, and birth cohort.
conclusionThe disease burden of respiratory infections in China exhibited a declining trend from 1990 to 2021. However, the risk of infection increased with age, highlighting the need for continued research and development of targeted measures to prevent respiratory infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.